tbuckley/cabot-search huggingface dataset:
Fractal Organization of the Human T Cell Repertoire in Health and Following Stem Cell Transplantation
Authors: Jeremy Meier, Allison F Hazlett, Kassi Avent, Jennifer Berrie, Kyle Payne, David Hamm, Cindy Desmarais, Catherine Sanders, Kevin T Hogan, Steven Grant, Kellie J Archer, Masoud H Manjili, Catherine Roberts, Amir A Toor
Journal: Blood (2012)
A Randomized Phase 2 Trial of Bortezomib–Dexamethasone Versus Bortezomib–Dexamethasone with Added Cyclophosphamide or Lenalidomide in Multiple Myeloma Patients Achieving Stable Disease After Four Cycles of Bortezomib–Dexamethasone Administered as Second-Line Treatment.
Authors: Meletios A. Dimopoulos, Huw Roddie, Meral Beksac, Lotfi Benboubker, Romualdas Jurgutis, Christian Langer, Javier de la Rubia, Luis Felipe Casado, Kazimierz Kuliczkowski, Lena Macukanovic-Golubovic, Thierry Facon
Journal: Blood (2009)
Impact of Additional Cytogenetic Changes and FLT3 Mutations on the Outcome of Patients with Newly Diagnosed Acute Promyelocytic Leukaemia Treated with Single Agent Arsenic Trioxide.
Authors: Vikram Mathews, Maria Thomas, Vivi M. Srivastava, Ezhilarasi Chendamarai, Biju George, Kavitha M. Lakshmi, Auro Viswabandya, Usha Sitaram, Mammen Chandy, Alok Srivastava
Journal: Blood (2006)
Abnormalities in Serum Free-Immunoglobulin Light Chains Show a High and Differential Frequency among WHO Subtypes of B-Cell Non-Hodgkin’s Lymphoma (NHL) and May Turn of Value for Therapeutic Monitoring: A Study of 354 Newly Diagnosed Patients
Authors: Antonio Pinto, Rosaria De Filippi, Giancarla Iaccarino, Raffaele Di Francia, Mariarosaria Distinto, Ferdinando Frigeri, Filippo Russo, Alessandro Marchei, Barbara Amoroso
Journal: Blood (2008)
Bi-Allelic Deletion of 13q14 Is Associated with Inferior Progression Free Survival Compared to Mono-Allelic 13q14 Deletion in B-Cell Chronic Lymphocytic Leukaemia.
Authors: Sheila J. O’Connor, Kathryn Turner, Sharon L. Barrans, Brad Dickinson, Andy C. Rawstron, Hazem Sayala, Paul Moreton, Roger G. Owen, Andrew S. Jack, Peter Hillmen
Journal: Blood (2005)
French surgeon is suspended for 12 months for not having UK licence
Authors: Clare Dyer
Journal: BMJ (2016)

A French orthopaedic surgeon has been suspended for 12 months by the UK Medical Practitioners Tribunal Service after he performed surgery at London’s Charing Cross Hospital and a private hospital without a UK licence to practise.

Xavier Ohl, who qualified at the University of Reims in 2008, was invited to undertake clinical and research activities in Britain. He was supported by a consultant orthopaedic surgeon named in the case only as Dr A, who stated in his supporting letter, “He is one of the brightest young orthopaedic surgeons of his …
Therapeutics for Brain Metastases, <i>v3</i>
Authors: Patricia S. Steeg, Alexandra Zimmer, Brunilde Gril
Journal: Clinical Cancer Research (2016)

The role of blood-brain barrier (BBB) permeability in the efficacy of brain metastasis therapeutics is debated. Both BBB-permeable and BBB-impermeable compounds were compared in a melanoma brain metastasis model using imaging through a cranial window. Only the BBB-permeable compound inhibited both the ∼30% permeable metastases and the ∼70% impermeable metastases. Clin Cancer Res; 22(24); 5953-5. ©2016 AACRSee related article by Osswald et al., p. 6078.
Junctional Adhesion Molecule-A/F11 Receptor (JAM-A/F11R) Is a Novel Biomarker and a Potential Treatment Target In Multiple Myeloma Tumor and Its Microvascular Milieu
Authors: Bani M Azari, Danielle F Joseph, Marc J Braunstein, H. Uwe Klueppelberg, Eric LP Smith, Sadeaqua Scott, Jonathan D Marmur, Anna Babinska, Olcay Batuman
Journal: Blood (2010)
STAT3, Constitutively Activated In ABC-Like DLBCL, Regulates Expression of the Prognostic Factor Cyclin D2
Authors: Julie Marie Matthews, Yasodha Natkunam, Sathish Srinivasan, Matt Patricelli, Tyzoon Nomanbhoy, Leandro Cerchietti, Ari M. Melnick, Izidore S Lossos
Journal: Blood (2010)
Assessment of Residual Bulky Tumor Using FDG-PET In Patients with Advanced-Stage Hodgkin Lymphoma After Completion of Chemotherapy: Final Report of the GHSG HD15 Trial
Authors: Andreas Engert, Carsten Kobe, Jana Markova, Heinz Haverkamp, Peter Borchmann, Felicitas Hitz, Josee Zijlstra, Hans Eich, Rolf-Peter Mueller, Markus Dietlein, Volker Diehl
Journal: Blood (2010)
Redirection of Immune Effector Cells by Bispecific Antibody Systems for the Treatment of Acute Myeloid Leukemia
Authors: Claudia Arndt, Anja Feldmann, Stefanie Koristka, Irene Michalk, Marc Cartellieri, Slava Stamova, Malte von Bonin, Martin Bornhäuser, Gerhard Ehninger, Michael Bachmann
Journal: Blood (2011)
Radioimmunotherapy-Based Conditioning with Yttrium-90 Ibritumomab Tiuxetan Plus High Dose BEAM for Non-Hodgkin Lymphoma: Does the Regimen Matter?
Authors: Amrita Y. Krishnan, Joycelynne Palmer, Auayporn P. Nademanee, Robert Chen, Leslie L. Popplewell, Nicole Tsai, James F. Sanchez, Jennifer Simpson, Ricardo Spielberger, Dave Yamauchi, Stephen J. Forman
Journal: Blood (2015)
Fc Engineered Anti-CD19 Monoclonal Antibodies with Enhanced In Vitro Efficacy Against Multiple Lymphoma Cell Lines.
Authors: Eugene A. Zhukovsky, Seung Chu, Matthew Bernett, Philip Hammond, Sher Karki, Wei Dang, Collin Edler, Nephi Polder, Cheryl Chan, Jonathan Jacinto, John Desjarlais
Journal: Blood (2006)
ATIM-05. COMPLEMENTARY CLINICAL AND ANCILLARY DATA FROM 123 PATIENTS WITH RECURRENT HIGH GRADE GLIOMA FROM THREE PHASE 1 TRIALS OF TOCA 511 AND TOCA FC: UPDATE AND JUSTIFICATION FOR A PHASE 2/3 TRIAL
Authors: Manish Aghi, Michael Vogelbaum, Steven Kalkanis, Daniela Bota, Bob Carter, Clark Chen, Bradley Elder, Johnathan Engh, Samuel Goldlust, George Kaptain, Santosh Kesari, Joseph Landolfi, Linda Liau, Tom Mikkelsen, David Piccioni, Jana Portnow, Samuel Singer, Tobias Walbert, Harry Gruber, Carlos Ibañez, Douglas Jolly, Leah Mitchell, Derek Ostertag, Jolene Shorr, Liqiang Yang, Asha Das, Timothy Cloughesy
Journal: Neuro-Oncology (2016)

Toca 511 (vocimagene amiretrorepvec) is an investigational, conditionally lytic, retroviral replicating vector. The vector infects human cells with selectivity for cancer cells because genome integration is dependent on cell division and viral replication is inhibited by innate and adaptive immune responses, defective in malignant tissues. Toca 511 spreads through cancer cells and stably delivers the gene for an optimized yeast cytosine deaminase that converts courses of the prodrug Toca FC (an investigational, extended-release version of 5-fluorocytosine) into 5-fluorouracil (5-FU). The 5-FU directly kills cancer cells likely leading to activation of antigen presenting cells in the tumor microenvironment. 5-FU can also diffuse into nearby immunosuppressive myeloid cells and kill them, leading to further activation of the immune system against the tumor by removing an important inflammatory brake. The safety, viral kinetics, immune response, and preliminary efficacy of Toca 511 and Toca FC have been investigated since 2010 in three, open-label, ascending dose, Phase 1 studies of 123 patients with recurrent high grade glioma (rHGG), each evaluating different methods of Toca 511 administration (intratumoral injection, injection into the cavity wall following resection, and intravenous injection followed by resection and injection into resection cavity wall) followed by multiple courses of oral Toca FC. Results to date include good tolerability; no persistent viremia; successful gene transduction within resected tumors; and median overall survival with stereotactic biopsy needle, resection cavity wall, and intravenous/cavity wall vector injection ranging from 12.1–13.6 months. Analysis of pretreatment resected tumor samples for mRNA expression patterns showed a survival-related signature that otherwise does not correlate with survival in publically available databases. Preliminary data from these studies supported initiation of a randomized, Phase 2/3 study in patients with rHGG (NCT02414165) in 2015. Updated and pooled safety data, immune response findings, and updated efficacy data for the Phase 1 studies will be presented.
Implications for the Use of Monoclonal Antibodies in Future Adult ALL Trials: Analysis of Antigen Expression in 505 B-Lineage (B-Lin) ALL Patients (pts) on the MRC UKALLXII/ECOG2993 Intergroup Trial.
Authors: Elisabeth Paietta, Xiaochun Li, Sue Richards, Janis Racevskis, Gordon W. Dewald, Jacob M. Rowe, Martin S Tallman, Hillard M Lazarus, Mark Litzow, Anthony H. Goldstone, Peter H. Wiernik
Journal: Blood (2008)
Acute change in glomerular filtration rate with inhibition of the renin-angiotensin system does not predict subsequent renal and cardiovascular outcomes
Authors: Catherine M. Clase, Joshua Barzilay, Peggy Gao, Andrew Smyth, Roland E. Schmieder, Sheldon Tobe, Koon K. Teo, Salim Yusuf, Johannes F.E. Mann
Journal: Kidney International (2016)
The Pan-Bcl-2 Family Inhibitor 97C1 Targets Blast Crisis Chronic Myeloid Leukemia Stem Cells but Spares Normal Cord Blood Progenitor Cells
Authors: Daniel Goff, Alice Shih, Angela Court Recart, Larisa Balaian, Ryan Chuang, Anil Sadarangani, Heather Leu, Qingfei Jiang, Annelie Schairer, Jennifer Black, Russell Wall, Christopher Kane, Christina Jamieson, Raymond J. Tesi, Catriona Jamieson
Journal: Blood (2010)
Measurement of HSP90 and HSP70 in CD34-Positive Cells: Lower Levels in Myelodysplastic Syndrome Than in Acute Myeloid Leukemia and Correlation with Clinical Behavior.
Authors: M. Gorre, I. Jilani, R. Chang, H. Chan, R. Urcia, M. Keating, H. Kantarjian, E. Estey, S. O’Brien, F. Giles, M. Albitar
Journal: Blood (2005)
Quantification by Magnetic Resonance Imaging (MRI) and Consequences of Post-Transfusionnal Iron Overload in Long Bone Marrow Transplant Survivors.
Authors: Christian Rose, Olivier Ernst, Bernard Hecquet, Pascale Renom, Marie Pierre Noel, Ibrahim Yakoub-Agha, Emmanuelle Bourgeois, Nathalie Cambier, Francis Bauters, Jean Pierre Jouet
Journal: Blood (2005)
Assessment of Safety and Efficacy of a New Intravenous Immunoglobulin (IGIV3I 10% Grifols) In Subjects with Chronic Immune Thrombocytopenia
Authors: Ali Khojasteh, Giraldo Kato, Nehal Parikh, Tammuella Singleton, Cameron K Tebbi, Caroline Cromwell, Chieh-Lin Fu, Craig M. Kessler, Jeffrey Letzer, Bruce Ritchie, Charles Sexauer, Kapil Saxena, Surendra Sirpal, Marcela Torres, Svetlana Loriya, Lidia Kovaleva, Virgilio Sandoval, Miguel A. Sanz, Antonio Julià, Maria Montañés, Jordi Navarro
Journal: Blood (2010)
MicroRNA-210 Enhances Fibrous Cap Stability in Advanced Atherosclerotic Lesions
Authors: Suzanne M. Eken, Hong Jin, Ekaterina Chernogubova, Yuhuang Li, Nancy Simon, Changyan Sun, Greg Korzunowicz, Albert Busch, Alexandra Bäcklund, Cecilia Österholm, Anton Razuvaev, Thomas Renné, Hans Henning Eckstein, Jaroslav Pelisek, Per Eriksson, María González Díez, Ljubica Perisic Matic, Isabel N. Schellinger, Uwe Raaz, Nicholas J. Leeper, Göran K. Hansson, Gabrielle Paulsson-Berne, Ulf Hedin, Lars Maegdefessel
Journal: Circulation Research (2016)

In the search for markers and modulators of vascular disease, microRNAs (miRNAs) have emerged as potent therapeutic targets.To investigate miRNAs of clinical interest in patients with unstable carotid stenosis at risk of stroke.Using patient material from the BiKE (Biobank of Karolinska Endarterectomies), we profiled miRNA expression in patients with stable versus unstable carotid plaque. A polymerase chain reaction-based miRNA array of plasma, sampled at the carotid lesion site, identified 8 deregulated miRNAs (miR-15b, miR-29c, miR-30c/d, miR-150, miR-191, miR-210, and miR-500). miR-210 was the most significantly downregulated miRNA in local plasma material. Laser capture microdissection and in situ hybridization revealed a distinct localization of miR-210 in fibrous caps. We confirmed that miR-210 directly targets the tumor suppressor gene APC (adenomatous polyposis coli), thereby affecting Wnt (Wingless-related integration site) signaling and regulating smooth muscle cell survival, as well as differentiation in advanced atherosclerotic lesions. Substantial changes in arterial miR-210 were detectable in 2 rodent models of vascular remodeling and plaque rupture. Modulating miR-210 in vitro and in vivo improved fibrous cap stability with implications for vascular disease.An unstable carotid plaque at risk of stroke is characterized by low expression of miR-210. miR-210 contributes to stabilizing carotid plaques through inhibition of APC, ensuring smooth muscle cell survival. We present local delivery of miR-210 as a therapeutic approach for prevention of atherothrombotic vascular events.
Delineation of the Common Developmental Pathway for Granulocyte/Monocyte and Lymphoid Lineages by Using an Expression Reporter for PU.1.
Authors: Yojiro Arinobu, Shin-ichi Mizuno, Hirokazu Shigematsu, Hidetoshi Ozawa, Yong Chong, Hiromi Iwasaki, Philippe Kastner, Susan Chan, Koichi Akashi
Journal: Blood (2006)
The IgM Flare Following Rituximab and IVIG Administration in Waldenstrom's Macroglobulinemia Is Related to IL-6 Production by Bystander Immune Cells, Possibly through Stimulation of the Fcgriia Receptor.
Authors: Guang Yang, Ping Gong, Thea Ioakimidis, Lian Xu, Zachary Hunter, Jenny Sun, Bryan Ciccarelli, Yangsheng Zhou, Xia Liu, Hsiuyi Tseng, Yang Cao, Robert Manning, Megan Lewicki, Christina Hanzis, Patricia Sheehy, Christopher J Patterson, Steven Treon
Journal: Blood (2009)
Lenalidomide Therapy Is Associated with Improvement of Peripheral Neuropathy in Patient with Relapsed/Refractory Multiple Myeloma: Preliminary Results From a Single-Centre Prospective Non Interventional Study.
Authors: Renato Zambello, Tamara Berno, Laura Candiotto, Chiara Dalla Torre, Marta Campagnolo, Marta Lucchetta, Livio Trentin, Chiara Briani, Gianpietro Semenzato
Journal: Blood (2009)
Plasma ADAMTS13 Activity Markedly Decreases in Patients with Severe Acute Pancreatitis: Its Potential Role on the Development of Multiorgan Failure.
Authors: Chie Morioka, Masahito Uemura, Tomomi Matsuyama, Masanori Matsumoto, Seiji Kato, Masatohsi Ishikawa, Hiromichi Ishizashi, Masao Fujimoto, Tatsuhiro Tsujimoto, Kenji Nishio, Kazuo Okuchi, Yoshihiro Fujimura, Hiroshi Fukui
Journal: Blood (2007)
Largazole, a Novel Cyclic Peptide Histone Deacetylase Inhibitor, Demonstrates Anti-MM Effects Alone and Increases the Anti-MM Effects of Bortezomib.
Authors: Zhi-Wei Li, Mengyin Hu, Crystal Leung, Jeffrey A Steinberg, Jing Shen, Mingjie Li, Cathy S Wang, Eric Sanchez, Albert Bowers, Thomas Greshock, Kenneth Miller, Tenaya Newkirk, Nathan West, James E. Bradner, Robert M Williams, Benjamin Bonavida, Haiming Chen, James R. Berenson
Journal: Blood (2009)
During Terminal Differentiation, HbF-Inducing Cytokines Cause Decreased Expression and Reduced Globin Locus Occupancy of BCL11A in Human Erythroblasts.
Authors: Orapan Sripichai, Christine M. Kiefer, Y. Terry Lee, Emily Riehm Meier, Colleen Byrnes, Ann Dean, Jeffery L. Miller
Journal: Blood (2009)
Assessment of Thrombotic Risk in Cancer Patients: Proposal of a Scoring System. A Monocentric Study.
Authors: Giulio Giordano, Giuliana Farina, Tambaro Rosa, Silvia Piano, Monica Specchia, Stefano Papini, Piero Modugno, Enrico Maria Centritto, Bruno Zappacosta, Sergio Storti
Journal: Blood (2007)
Autologous (Auto) Peripheral Blood Stem Cell (SCT) As a Consolidation Therapy for Patients with Acute Myeloid Leukemia (AML) in 1st Complete Remission (CR): A Single Institution Experience
Authors: Amanpreet Buttar, Deepa Jagadeesh, Jan Cerny, Muthalagu Ramanathan, Zheng Zhou, Laura Petrillo-Deluca, Natasha Tarrasky, Jayde Bednarik, Zankar Desai, William V Walsh, Rajneesh Nath
Journal: Blood (2011)
Mechanosensory hair cells express two molecularly distinct mechanotransduction channels
Authors: Zizhen Wu, Nicolas Grillet, Bo Zhao, Christopher Cunningham, Sarah Harkins-Perry, Bertrand Coste, Sanjeev Ranade, Navid Zebarjadi, Maryline Beurg, Robert Fettiplace, Ardem Patapoutian, Ulrich Müller
Journal: Nature Neuroscience (2016)
HIF-1 Supports the Survival of Multiple Myeloma Cells through the Induction of Survivin Gene.
Authors: Keita Kirito, Hu Yongzhen, Kozue Yoshida, Toru Mitsumori, Kei Nakajima, Yumi Nozaki, Takahiro Nagashima, Masae Kunitama, Kumi Sakoe, Norio Komatsu
Journal: Blood (2007)
Induction of Immune Responses and Improved Survival after Infusions of T Cells Armed with Anti-CD3 X Anti-Her2/Neu Bispecific Antibody in Stage IV Breast Cancer Patients (Phase I).
Authors: Lawrence G. Lum, Ritesh Rathore, Don Dizon, Ding Wang, Zaid Al-Kadhimi, Joseph P. Uberti, Voravit Ratanatharathorn
Journal: Blood (2007)
HHV8 Associated Multicentric Castleman's Disease In a HIV Negative Patient Responding to Treatment with Bortezomib and Gancyclovir- A Novel Therapy for An Orphan Disease
Authors: Maria M. Sbenghe, Amit Mahipal, Alina Dulau Florea, Emmanuel C. Besa, Paul Bray, Jaime Caro
Journal: Blood (2010)
Sixty seconds on . . . solanezumab
Authors: Nigel Hawkes
Journal: BMJ (2016)

Yes, another drug has failed in phase III trials. This one is solanezumab, whose demise was a three act drama that’s finally seen the curtain fall.1 2 3

Not really. Alzheimer’s disease is the graveyard of drug discovery. One study found that of 244 compounds tested between 2000 and 2014 only one was ever licensed, a failure rate of 99.6%.4

Or …
Conditioning with Fludarabine (Flu)-Alkylator Is More Effective Cytoreduction Than Cyclophosphamide-Total Body Irradiation (Cy/TBI) for Refractory, Progressive Chronic Lymphatic Leukemia (CLL).
Authors: Andrew C. Grigg, Jeffrey Szer, Andrew Artz, Justin Kline, Koen van Besien
Journal: Blood (2004)
Heterogeneity of Acute Myeloid Leukemia at the Stem Cell Level.
Authors: Michael Heuser, Laura Sly, Courteney Lai, Malina Leung, Grace Lin, Bob Argiropoulos, Florian Kuchenbauer, Stephen Fung, Christy Brookes, Gerald Krystal, R. Keith Humphries
Journal: Blood (2008)
Sandcastle Worm‐Inspired Blood‐Resistant Bone Graft Binder Using a Sticky Mussel Protein for Augmented In Vivo Bone Regeneration
Authors: Hyo Jeong Kim, Bong‐Hyuk Choi, Sang Ho Jun, Hyung Joon Cha
Journal: Advanced Healthcare Materials (2016)

Xenogenic bone substitutes are commonly used during orthopedic reconstructive procedures to assist bone regeneration. However, huge amounts of blood accompanied with massive bone loss usually increase the difficulty of placing the xenograft into the bony defect. Additionally, the lack of an organic matrix leads to a decrease in the mechanical strength of the bone‐grafted site. For effective bone grafting, this study aims at developing a mussel adhesion‐employed bone graft binder with great blood‐resistance and enhanced mechanical properties. The distinguishing water (or blood) resistance of the binder originates from sandcastle worm‐inspired complex coacervation using negatively charged hyaluronic acid (HA) and a positively charged recombinant mussel adhesive protein ( r MAP) containing tyrosine residues. The r MAP/HA coacervate stabilizes the agglomerated bone graft in the presence of blood. Moreover, the r MAP/HA composite binder enhances the mechanical and hemostatic properties of the bone graft agglomerate. These outstanding features improve the osteoconductivity of the agglomerate and subsequently promote in vivo bone regeneration. Thus, the blood‐resistant coacervated mussel protein glue is a promising binding material for effective bone grafting and can be successfully expanded to general bone tissue engineering.
Circulating Plasma Cells in Newly Diagnosed Symptomatic Multiple Myeloma As a Prognostic Marker for Patients with Standard-Risk Cytogenetics
Authors: Davide Vagnoni, Fosco Travaglini, Stefano Angelini, Alessia Dalsass, Francesca Mestichelli, Mario Angelini, Valerio Pezzoni, Annalisa Natale, Miriana Ruggieri, Catia Bigazzi, Emanuela Troiani, Sadia Falcioni, Serena Mazzotta, Piero Galieni
Journal: Blood (2014)
Haploidentical Mismatched Allogeneic Versus Autologous Hematopoietic STEM CELL Transplantation in Adult Patients with ACUTE Myeloid Leukemia (AML) in First Complete Remission (CR1): A Pair-Matched Analysis From the Acute Leukemia Working Party of EBMT.
Authors: Norbert C. Gorin, Myriam Labopin, Fabio Ciceri, Andrea Velardi, Stella Santarone, William Arcese, Mohamad Mohty
Journal: Blood (2012)
Standard Induction Followed by Attenuated Consolidation Therapy in Elderly Patients with Acute Myeloid Leukemia.
Authors: Je-Hwan Lee, Seong-Jun Choi, Jung-Hee Lee, Miee Seol, Keun Hee Kim, Jae-Hoo Park, Hawk Kim, Young-Don Joo, Won Sik Lee, Dae Young Zang, Hyo Jung Kim, Kyoo-Hyung Lee
Journal: Blood (2005)
Kinetics of Bone Marrow Blasts during Remission Induction Course in Acute Myeloid Leukemia: Effect on Complete Remission and Relapse-Free Survival.
Authors: Masamitsu Yanada, Guillermo Garcia-Manero, Farhad Ravandi, Stefan Faderl, Hagop Kantarjian, Elihu Estey
Journal: Blood (2007)
Infusion of Red Blood Cell-Derived Microparticles (RMPs) Reduced Intracerebral Bleeding Following Hemorrhagic Stroke in a Rat Model
Authors: Kunjan R Dave, Sebastian Koch, Vibha Shukla, Isabel Saul, Carlos Bidot, Allen Liu, Miguel Perez-Pinzon, Wenche Jy, Yeon-Soong Ahn
Journal: Blood (2014)
Co-Transplantation Haploidentical Mesenchymal Stem Cells and Hematoietic Stem Cells with Nonmyeloablative Condition for Treatment of Relapsed or Refractory Acute Leukaemia.
Authors: Hui-Sheng Ai, Mei Guo, Chang-Lin Yu, Dan-Hong Wang, Jian-Hui Qiao, Qi-Yun Sun, Li-Hui Liu, Zhang Shi, Robert Chunhua Zhao, Zhao Sun
Journal: Blood (2005)
Identification of New Upregulated Genes with Possible Relevance for Multiple Myeloma Tumorigenesis
Authors: Roberta Spetic Felix, Gisele W. B. Colleoni, Otavia L. Caballero, Manuella Sampaio Almeida, Valeria C.C. Andrade, Maria L. L. F. Chauffaille, Wilson A. Silva, Maria Dirlei Begnami, Fernando Augusto Soares, Marco Antonio Zago, Andre Luiz Vettore
Journal: Blood (2008)
Determinants of fatal bleeding during induction therapy for acute promyelocytic leukemia in the ATRA era
Authors: Simon Mantha, Debra A. Goldman, Sean M. Devlin, Ju-Whei Lee, Diana Zannino, Marnie Collins, Dan Douer, Harry J. Iland, Mark R. Litzow, Eytan M. Stein, Frederick R. Appelbaum, Richard A. Larson, Richard Stone, Bayard L. Powell, Susan Geyer, Kristina Laumann, Jacob M. Rowe, Harry Erba, Steven Coutre, Megan Othus, Jae H. Park, Peter H. Wiernik, Martin S. Tallman
Journal: Blood (2017)